Pharvaris (PHVS) Stock Forecast, Price Target & Predictions

PHVS Stock Forecast

Pharvaris stock forecast is as follows: an average price target of $42.00 (represents a 138.10% upside from PHVS’s last price of $17.64) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.

PHVS Price Target

The average price target for Pharvaris (PHVS) is $42.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $42.00 to $42.00. This represents a potential 138.10% upside from PHVS's last price of $17.64.

PHVS Analyst Ratings

Buy

According to 4 Wall Street analysts, Pharvaris's rating consensus is 'Buy'. The analyst rating breakdown for PHVS stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Pharvaris Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Oct 14, 2024	Justin Kim	Oppenheimer	$42.00	$19.73	112.87%	138.10%
Apr 11, 2024	Jonathan Wolleben	JMP Securities	$50.00	$22.27	124.52%	183.45%
Sep 25, 2023	Laura Chico	Wedbush	$27.00	$20.67	30.62%	53.06%
Jan 11, 2023		JMP Securities	$23.00	$10.32	122.87%	30.39%
Dec 09, 2022		JMP Securities	$22.00	$11.46	91.97%	24.72%

The latest Pharvaris stock forecast, released on Oct 14, 2024 by Justin Kim from Oppenheimer, set a price target of $42.00, which represents a 112.87% increase from the stock price at the time of the forecast ($19.73), and a 138.10% increase from PHVS last price ($17.64).

Pharvaris Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	2
Avg Price Target	-	-	$46.00
Last Closing Price	$17.64	$17.64	$17.64
Upside/Downside	-100.00%	-100.00%	160.77%

In the current month, the average price target of Pharvaris stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Pharvaris's last price of $17.64. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 14, 2024	Oppenheimer	Outperform	Outperform	Hold
Sep 06, 2024	Oppenheimer	Outperform	Outperform	Hold
Jul 03, 2024	Oppenheimer	Outperform	Outperform	Hold
Aug 15, 2023	Morgan Stanley		Overweight	Upgrade
Feb 03, 2023	SVB Leerink	Outperform	Outperform	Hold
Jan 11, 2023	JMP Securities	Market Outperform	Market Outperform	Hold
Dec 09, 2022	JMP Securities	Market Outperform	Market Outperform	Hold

Pharvaris's last stock rating was published by Oppenheimer on Oct 14, 2024. The company gave PHVS a "Outperform" rating, the same as its previous rate.

Pharvaris Financial Forecast

Pharvaris Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
Revenue	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	$7.60M	$2.38M	-	-	-	-	-	-	-	-	-
High Forecast	$7.60M	$2.38M	-	-	-	-	-	-	-	-	-
Low Forecast	$7.60M	$2.38M	-	-	-	-	-	-	-	-	-
# Analysts	1	1	-	-	-	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-	-	-	-	-

Pharvaris's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. PHVS's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Pharvaris EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	1	1	-	-	-	-	-	-	-	-	-
EBITDA	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	-	-	-	-	-	-	-	-	-	-	-
High Forecast	-	-	-	-	-	-	-	-	-	-	-
Low Forecast	-	-	-	-	-	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-	-	-	-	-

undefined analysts predict PHVS's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Pharvaris's previous annual EBITDA (undefined) of $NaN.

Pharvaris Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	1	1	-	-	-	-	-	-	-	-	-
Net Income	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	$-50.74M	$-52.79M	$-50.23M	$-37.93M	$-42.56M	$-41.48M	$-41.11M	$-40.37M	$-40.60M	$-35.56M	$-31.88M
High Forecast	$-50.74M	$-52.79M	$-50.23M	$-37.93M	$-42.56M	$-41.48M	$-41.11M	$-39.80M	$-33.75M	$-35.56M	$-31.88M
Low Forecast	$-50.74M	$-52.79M	$-50.23M	$-37.93M	$-42.56M	$-41.48M	$-41.11M	$-40.94M	$-53.25M	$-35.56M	$-31.88M
Surprise %	-	-	-	-	-	-	-	-	-	-	-

Pharvaris's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. PHVS's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Pharvaris SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	1	1	-	-	-	-	-	-	-	-	-
SG&A	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	-	-	-	-	-	-	-	-	-	-	-
High Forecast	-	-	-	-	-	-	-	-	-	-	-
Low Forecast	-	-	-	-	-	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-	-	-	-	-

Pharvaris's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to PHVS last annual SG&A of $NaN (undefined).

Pharvaris EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	1	1	-	-	-	-	-	-	-	-	-
EPS	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	$-0.94	$-0.98	$-0.93	$-0.70	$-0.79	$-0.77	$-0.76	$-0.75	$-0.75	$-0.66	$-0.59
High Forecast	$-0.94	$-0.98	$-0.93	$-0.70	$-0.79	$-0.77	$-0.76	$-0.74	$-0.63	$-0.66	$-0.59
Low Forecast	$-0.94	$-0.98	$-0.93	$-0.70	$-0.79	$-0.77	$-0.76	$-0.76	$-0.99	$-0.66	$-0.59
Surprise %	-	-	-	-	-	-	-	-	-	-	-

According to undefined Wall Street analysts, Pharvaris's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to PHVS previous annual EPS of $NaN (undefined).

Pharvaris Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
PEPG	PepGen	$1.84	$29.50	1503.26%	Buy
HOWL	Werewolf Therapeutics	$1.34	$12.00	795.52%	Buy
ANTX	AN2 Therapeutics	$1.18	$8.75	641.53%	Buy
MOLN	Molecular Partners	$5.22	$29.00	455.56%	Buy
PMVP	PMV Pharmaceuticals	$1.43	$6.00	319.58%	Buy
ANEB	Anebulo Pharmaceuticals	$1.54	$6.00	289.61%	Buy
MLYS	Mineralys Therapeutics	$10.36	$30.00	189.58%	Buy
STOK	Stoke Therapeutics	$10.51	$26.50	152.14%	Buy
PHVS	Pharvaris	$17.64	$42.00	138.10%	Buy
TYRA	Tyra Biosciences	$14.65	$31.75	116.72%	Buy
DSGN	Design Therapeutics	$4.94	$9.67	95.75%	Buy
JANX	Janux Therapeutics	$42.51	$70.25	65.26%	Buy
RZLT	Rezolute	$5.06	$6.67	31.82%	Buy
IKNA	Ikena Oncology	$1.50	$1.33	-11.33%	Buy

PHVS Forecast FAQ

Is Pharvaris a good buy?

Yes, according to 4 Wall Street analysts, Pharvaris (PHVS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of PHVS's total ratings.

What is PHVS's price target?

Pharvaris (PHVS) average price target is $42 with a range of $42 to $42, implying a 138.10% from its last price of $17.64. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Pharvaris stock go up soon?

According to Wall Street analysts' prediction for PHVS stock, the company can go up by 138.10% (from the last price of $17.64 to the average price target of $42), up by 138.10% based on the highest stock price target, and up by 138.10% based on the lowest stock price target.

Can Pharvaris stock reach $30?

PHVS's average twelve months analyst stock price target of $42 supports the claim that Pharvaris can reach $30 in the near future.

What are Pharvaris's analysts' financial forecasts?

Pharvaris's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-166M (high $-165M, low $-166M), average SG&A $0 (high $0, low $0), and average EPS is $-3.068 (high $-3.058, low $-3.079). PHVS's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $9.98M (high $9.98M, low $9.98M), average EBITDA is $0 (high $0, low $0), average net income is $-192M (high $-192M, low $-192M), average SG&A $0 (high $0, low $0), and average EPS is $-3.554 (high $-3.554, low $-3.554).